Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 184 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: lapatinib (GW572016) Clear all
Completed Phase 2 Interventional Results available

Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

NCT00709761
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib/nab-Paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
13
States / cities
La Verne, California • Long Beach, California • Fort Myers, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 2, 2026, 2:31 AM EDT
Terminated Phase 2 Interventional Results available

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

NCT01934894
View directory record Official record
Conditions
Metastatic Breast Cancer With Intracranial Metastases
Interventions
cabazitaxel, lapatinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

NCT01272141
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Cancer of the Breast
Interventions
Lapatinib and Everolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00246753
View directory record Official record
Conditions
Prostate Cancer
Interventions
lapatinib ditosylate
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Withdrawn Phase 1Phase 2 Interventional

INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients

NCT00455039
View directory record Official record
Conditions
Breast Cancer
Interventions
GW572016
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

NCT00826267
View directory record Official record
Conditions
Breast Neoplasms
Interventions
lapatinib, BIBW 2992, trastuzumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

NCT00482391
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

NCT00430781
View directory record Official record
Conditions
Neoplasms, Uterine Cervix, Metastatic Cervical Cancer
Interventions
pazopanib (GW786034), lapatinib (GW572016)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 2, 2026, 2:31 AM EDT
Terminated Phase 2 Interventional Results available

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

NCT00759642
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
lapatinib
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Kansas City, Kansas • Topeka, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

NCT00558103
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
17
States / cities
Long Beach, California • Sacramento, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 2, 2026, 2:31 AM EDT
Completed No phase listed Observational

Chemotherapeutic Agents in Brain/Breast

NCT00795678
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

NCT00320385
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
87
States / cities
Phoenix, Arizona • Sedona, Arizona • Highland, California + 79 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2016 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

NCT00075270
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Paclitaxel, GW572016 (Lapatinib)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
45
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

NCT02581124
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Lapatinib
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Lapatinib and Bevacizumab for Metastatic Breast Cancer

NCT00444535
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
lapatinib, bevacizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
9
States / cities
Tucson, Arizona • San Francisco, California • Hollywood, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

NCT00388076
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Pazopanib, Lapatinib, paclitaxel, carboplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
New Brunswick, New Jersey • Cleveland, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

NCT01160211
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab, Aromatase Inhibitor
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
4
States / cities
Hollywood, Florida • Augusta, Georgia • Germantown, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 2, 2026, 2:31 AM EDT
Terminated Not applicable Interventional Results available

Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast

NCT00857714
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
lapatinib
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 2, 2026, 2:31 AM EDT
Terminated Phase 3 Interventional Results available

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

NCT00968968
View directory record Official record
Conditions
Cancer
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
112
States / cities
Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 2, 2026, 2:31 AM EDT
Not listed Phase 2 Interventional

Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

NCT01283789
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lapatinib and RAD-001
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

NCT00662636
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dasatinib, lapatinib ditosylate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Results available

Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer

NCT00470847
View directory record Official record
Conditions
Breast Cancer, Brain Metastases
Interventions
Lapatinib, Whole Brain Radiation, Herceptin
Drug · Procedure
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 2, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

NCT01612351
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Carboplatin, Paclitaxel, Lapatinib, Cisplatin, Ipsilateral Radiation, Bilateral Radiation, Transoral Surgery
Drug · Radiation · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 2, 2026, 2:31 AM EDT